These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15622495)

  • 1. Can metallothionein be a useful molecular marker for selecting hepatocellular carcinoma patients for platinum-based chemotherapy?
    Doki Y; Monden M
    J Gastroenterol; 2004 Dec; 39(12):1228-9. PubMed ID: 15622495
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents.
    Endo T; Yoshikawa M; Ebara M; Kato K; Sunaga M; Fukuda H; Hayasaka A; Kondo F; Sugiura N; Saisho H
    J Gastroenterol; 2004 Dec; 39(12):1196-201. PubMed ID: 15622485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers for microvascular invasion in hepatocellular carcinoma: where do we stand?
    Gouw AS; Balabaud C; Kusano H; Todo S; Ichida T; Kojiro M
    Liver Transpl; 2011 Oct; 17 Suppl 2():S72-80. PubMed ID: 21714066
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
    Marquardt JU; Galle PR; Teufel A
    Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
    [No Abstract]   [Full Text] [Related]  

  • 6. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA; Mountzios G; Soria JC
    Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dimensional biology to comprehend hepatocellular carcinoma.
    Vivekanandan P; Singh OV
    Expert Rev Proteomics; 2008 Feb; 5(1):45-60. PubMed ID: 18282123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megestrol treatment in patients with hepatocellular carcinoma.
    Farinati F; Gianni S; De Giorgio M; Fiorentini S
    Br J Cancer; 2001 Nov; 85(10):1606-8. PubMed ID: 11720452
    [No Abstract]   [Full Text] [Related]  

  • 9. Diamminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma.
    Melia WM; Westaby D; Williams R
    Clin Oncol; 1981 Dec; 7(4):275-80. PubMed ID: 6172230
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunohistochemical analysis in hepatocellular carcinoma: does age matter?
    Yeh MM
    Am J Clin Pathol; 2005 Oct; 124(4):491-3. PubMed ID: 16146817
    [No Abstract]   [Full Text] [Related]  

  • 11. Aromatase inhibitors may be effective in the management of advanced hepatocellular carcinoma.
    Altundag O; Altundag K; Turen S; Gunduz E; Atik MA
    Med Hypotheses; 2006; 66(6):1257. PubMed ID: 16154711
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting chemokines as a therapeutic option for hepatocellular carcinoma: a reality or just a fantasy?
    Yu J
    J Gastroenterol Hepatol; 2007 May; 22(5):611-2. PubMed ID: 17444845
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant interferon for hepatocellular carcinoma.
    Okada S; Sato T; Yamamoto S
    Hepatology; 2001 Feb; 33(2):481-2. PubMed ID: 11172357
    [No Abstract]   [Full Text] [Related]  

  • 14. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P
    Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Searching for biological markers of molecular targeting treatment of liver cancer.
    Arao T; Kudo M; Nishio K
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1879-82. PubMed ID: 21069943
    [No Abstract]   [Full Text] [Related]  

  • 16. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma.
    Llovet JM; Paradis V; Kudo M; Zucman-Rossi J
    Liver Transpl; 2011 Oct; 17 Suppl 2(Suppl 2):S67-71. PubMed ID: 21594967
    [No Abstract]   [Full Text] [Related]  

  • 17. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
    Boulikas T; Stathopoulos GP; Volakakis N; Vougiouka M
    Anticancer Res; 2005; 25(4):3031-9. PubMed ID: 16080562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor-mediated protection of normal hepatocytes during chemotherapy for hepatocellular carcinoma.
    Keegan-Rogers V; Wu CH; Wu GY
    Targeted Diagn Ther; 1991; 4():105-25. PubMed ID: 1665717
    [No Abstract]   [Full Text] [Related]  

  • 19. [Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports].
    Kato H; Nagano H; Ota H; Nakamura M; Wada H; Yoshioka S; Noda T; Bazarragchaa D; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Murakami T; Nakamura H; Monden M
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1842-5. PubMed ID: 16315958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy for hepatocellular carcinoma.
    Thomas MB
    Cancer J; 2008; 14(2):123-7. PubMed ID: 18391618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.